M&T Bank Corp Reduces Holdings in Humana Inc. (NYSE:HUM)

M&T Bank Corp decreased its holdings in Humana Inc. (NYSE:HUM) by 13.2% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 8,437 shares of the insurance provider’s stock after selling 1,288 shares during the quarter. M&T Bank Corp’s holdings in Humana were worth $2,140,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently made changes to their positions in the business. Victory Capital Management Inc. boosted its holdings in shares of Humana by 73.5% in the fourth quarter. Victory Capital Management Inc. now owns 184,937 shares of the insurance provider’s stock worth $46,920,000 after buying an additional 78,351 shares during the last quarter. Commerzbank Aktiengesellschaft FI boosted its holdings in shares of Humana by 19.0% in the fourth quarter. Commerzbank Aktiengesellschaft FI now owns 6,074 shares of the insurance provider’s stock worth $1,541,000 after buying an additional 969 shares during the last quarter. Charles Schwab Investment Management Inc. boosted its holdings in shares of Humana by 7.3% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 964,926 shares of the insurance provider’s stock worth $244,811,000 after buying an additional 65,735 shares during the last quarter. Schechter Investment Advisors LLC purchased a new position in shares of Humana in the fourth quarter worth approximately $244,000. Finally, Fidelis Capital Partners LLC purchased a new position in shares of Humana in the fourth quarter worth approximately $225,000. Hedge funds and other institutional investors own 92.38% of the company’s stock.

Humana Trading Down 2.2 %

Shares of HUM opened at $259.86 on Monday. The company’s fifty day moving average is $271.80 and its 200 day moving average is $283.10. Humana Inc. has a fifty-two week low of $213.31 and a fifty-two week high of $406.46. The stock has a market capitalization of $31.35 billion, a PE ratio of 26.12, a P/E/G ratio of 2.05 and a beta of 0.57. The company has a debt-to-equity ratio of 0.68, a quick ratio of 1.76 and a current ratio of 1.76.

Humana (NYSE:HUM) last announced its quarterly earnings results on Tuesday, February 11th. The insurance provider reported ($2.16) earnings per share for the quarter, topping the consensus estimate of ($2.26) by $0.10. Humana had a net margin of 1.02% and a return on equity of 11.70%. Sell-side analysts expect that Humana Inc. will post 16.47 earnings per share for the current fiscal year.

Humana Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, April 25th. Shareholders of record on Friday, March 28th will be given a dividend of $0.885 per share. This represents a $3.54 dividend on an annualized basis and a yield of 1.36%. The ex-dividend date of this dividend is Friday, March 28th. Humana’s dividend payout ratio (DPR) is 35.58%.

Insider Buying and Selling at Humana

In other Humana news, insider Timothy S. Huval sold 3,703 shares of the business’s stock in a transaction on Tuesday, December 31st. The shares were sold at an average price of $256.26, for a total transaction of $948,930.78. Following the transaction, the insider now owns 8,181 shares in the company, valued at $2,096,463.06. The trade was a 31.16 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Company insiders own 0.32% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities research analysts have commented on the stock. Royal Bank of Canada restated an “outperform” rating and set a $283.00 target price on shares of Humana in a research note on Wednesday, February 12th. Truist Financial raised their target price on shares of Humana from $260.00 to $290.00 and gave the stock a “hold” rating in a research note on Monday, January 6th. StockNews.com cut shares of Humana from a “buy” rating to a “hold” rating in a research note on Wednesday, March 5th. Piper Sandler raised their target price on shares of Humana from $270.00 to $288.00 and gave the stock a “neutral” rating in a research note on Wednesday, January 15th. Finally, Barclays raised their target price on shares of Humana from $255.00 to $270.00 and gave the stock an “equal weight” rating in a research note on Thursday, February 13th. Twenty research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, Humana currently has an average rating of “Hold” and a consensus price target of $285.68.

Humana Company Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.